The vaccine against meningococcus exists as a single vaccine and as a conjugate vaccine with 4 strains.
Meningococcal B Vaccines
Bexsero - GlaxoSmithKline (click to open)
Meningococcal group B vaccine (rDNA, component, adsorbed)
Dosage declared by the manufacturer
Bexsero is given to individuals aged 2 months and older.
Adverse events declared by the manufacturer
- Pain/tenderness at the injection site
- Redness at the injection site
- Swelling at the injection site
- Induration at the injection site
- Fever (≥ 38 °C)
- Loss of appetite
- Irritability
- Threw up
- Diarrhea
- Drowsiness
- Unusual cry
- Joint pain
- Rash
- Headache (cephalea)
- Muscle pain (myalgia)
- Nausea
- Extensive swelling of the vaccinated limb
- High fever (≥ 40 °C)
- Seizures (including febrile seizures)
- Hypotonic-hyporesponsive episode
- Irritation of the meninges (neck stiffness or photophobia)
- Pallor
- Dry skin
- Eczema
- Kawasaki syndrome
- Urticaria
- Itchy skin rash
- Allergic reactions (including anaphylactic reactions)
- Swollen lymph nodes
- Feeling faint or fainting
- Collapse (sudden muscle flaccidity)
- Injection site reactions such as blisters or nodules that may persist for more than a month
Composition declared by the manufacturer
- Recombinant NHBA fusion protein Neisseria meningitidis group B (50 micrograms)
- Recombinant NadA protein Neisseria meningitidis group B (50 micrograms)
- Recombinant fusion protein fHbp of Neisseria meningitidis group B (50 micrograms)
- Outer membrane vesicles (OMV) of Neisseria meningitidis group B, strain NZ98/254, containing PorA P1.4 (25 micrograms)
- Aluminum hydroxide (0,5 mg Al³⁺)
- Sodium chloride
- Histidine
- Sucrose
- Water for injections
Trumenba - Pfizer (click to open)
Trumenba is a vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B, used in subjects aged 10 years and older.
Dosage declared by the manufacturer
Trumenba is given to individuals aged 10 years and older.
Adverse events declared by the manufacturer
- Redness at the injection site
- Swelling at the injection site
- Injection site pain
- Headache
- Diarrhea
- Nausea
- Muscular pains
- Articolar pains
- Chills
- Fatigue
- Threw up
- Fever (≥ 38°C)
- Allergic reactions
Composition declared by the manufacturer
- fHbp of Neisseria meningitidis serogroup B subfamily A (60 micrograms)
- fHbp of Neisseria meningitidis serogroup B subfamily B (60 micrograms)
- Aluminum phosphate (0,25 mg aluminum per dose)
- Sodium chloride
- Histidine
- Water for injections
- Polysorbate 80 (E433)
Meningococcal C Vaccines
Menjugate - GlaxoSmithKline (click to open)
Menjugate is a vaccine used to prevent disease caused by the bacterium Neisseria meningitidis group C (also called group C meningococcus).
Dosage declared by the manufacturer
Menjugate is given to individuals aged 2 months and older.
Adverse events declared by the manufacturer
- Redness at the injection site
- Swelling at the injection site
- Tenderness/pain at the injection site
- Fever (≥38°C)
- Irritability
- Drowsiness
- Sleep disorders
- lack of appetite
- Diarrhea
- Threw up
- General malaise
- Headache (cephalea)
- Myalgia (muscle pain)
- Arthralgia (joint pain)
- Dizziness
- fainting
- Numbness
- Tingling or stinging sensation
- Temporary reduction in muscle tone
- Visual disturbances
- Sensitivity to light (photophobia)
- Enlarged lymph nodes
- Seizures (including febrile seizures)
- Hypotonia
- Skin rashes
- Urticaria
- itch
- Purple
- erythema multiforme
- Stevens-Johnson Syndrome
- Extensive swelling of the vaccinated limb
- Relapse of nephrotic syndrome
Composition declared by the manufacturer
- Oligosaccharide of Neisseria meningitidis group C (strain C11) (10 micrograms)
- Protein CRM197 of Corynebacterium diphtheriae (12,5 to 25 micrograms)
- Aluminum hydroxide (0,3-0,4 mg Al³⁺)
- Sodium chloride
- Histidine
- Water for injections
NEISVAC-C - Pfizer (click to open)
NeisVac-C is a vaccine to prevent invasive meningococcal disease, caused by Neisseria meningitidis group C.
Dosage declared by the manufacturer
NeisVac-C is administered to subjects aged 2 months and older.
Adverse events declared by the manufacturer
- Redness at the injection site
- Swelling at the injection site
- Tenderness/pain at the injection site
- Temperature
- Irritability
- fatigue
- Torpor
- Drowsiness
- Cry
- Threw up
- Decreased appetite
- Stiffness at the injection site
- Headache (cephalea)
- Diarrhea
- Sore throat
- A runny nose
- Tosse
- Sleep disorders
- Skin rash
- Increased sweating
- Feeling unwell
- Dizziness
- Nausea
- Bellyache
- Pain in the arms or legs
- itch
- Bruises
- Skin inflammation
- Swollen lymph glands
- Allergic reaction (including difficulty breathing)
- Convulsive attacks
- Nasal congestion
- Collapse
- Apnea (in premature babies)
- Idiopathic thrombocytopenic purpura
- Skin rashes, urticaria, erythema
- Stevens-Johnson Syndrome
- Hyperhidrosis (excessive sweating)
- Nephrotic syndrome
Composition declared by the manufacturer
- Polysaccharide (de-O-acetylated) of the Neisseria meningitidis group C (strain C11) (10 micrograms)
- Tetanus toxoid (10-20 micrograms)
- Hydrated aluminum hydroxide (0,5 mg Al³⁺)
- Sodium chloride
- Water for injections
Anti-Meningococcal Conjugate Vaccine A, C, W135, Y
Menveo - GlaxoSmithKline (click to open)
Menveo is a vaccine used for the active immunization of children (from the age of 2 years), adolescents and adults at risk of exposure to serogroups A, C, W-135 and Y of a bacterium called Neisseria meningitidis.
Dosage declared by the manufacturer
Menveo is given to individuals aged 2 years and older.
Adverse events declared by the manufacturer
- Injection site pain
- Redness at the injection site
- Swelling at the injection site
- Injection site hardening
- Fever (≥38°C)
- Headache (cephalea)
- Drowsiness
- Irritability
- Nausea
- Threw up
- Diarrhea
- Muscle pain (myalgia)
- Joint pain (arthralgia)
- Chills
- Feeling unwell
- Skin eruption (rash)
- Injection site pruritus
- Dizziness
- Severe allergic reactions (including swelling of the lips, mouth and throat)
- fainting
- Skin infection at the injection site
- Seizures, including febrile seizures
- Extensive swelling of the limb at the injection site
Composition declared by the manufacturer
- Meningococcal group A oligosaccharide (10 micrograms) conjugated to CRM197 protein
- Meningococcal group C oligosaccharide (5 micrograms) conjugated to CRM197 protein
- Oligosaccharide of the meningococcal W-135 group (5 micrograms) conjugated to the CRM197 protein
- Meningococcal Y group oligosaccharide (5 micrograms) conjugated to CRM197 protein
- Potassium dihydrogen phosphate
- Sucrose
- Sodium chloride
- Sodium dihydrogen phosphate monohydrate
- Sodium hydrogen phosphate dihydrate
- Water for injections
Nimenrix - Pfizer (click to open)
Nimenrix is a vaccine that helps protect against infections caused by bacteria (germs) called “Neisseria meningitidis” types A, C, W-135 and Y of a bacterium called Neisseria meningitidis.
Dosage declared by the manufacturer
Nimenrix is administered to subjects aged 0 months and older.
Adverse events declared by the manufacturer
- Temperature
- Tiredness (fatigue)
- Headache (cephalea)
- Drowsiness
- Loss of appetite
- Irritability
- Swelling at the injection site
- Injection site pain
- Redness at the injection site
- Bruising (hematoma) at the injection site
- Diarrhea
- Threw up
- Nausea
- Rash
- itch
- Urticaria
- Cry
- Dizziness
- Muscle pain (myalgia)
- Pain in the arms or legs
- General malaise
- Difficulty sleeping (insomnia)
- Hypoesthesia (reduction of sensations)
- Injection site hardening
- Injection site pruritus
- Sensation of heat at the injection site
- Extensive swelling of the limb at the injection site
Composition declared by the manufacturer
- Group A polysaccharide Neisseria meningitidis (5 micrograms)
- Polysaccharide of group C Neisseria meningitidis (5 micrograms)
- Polysaccharide of the W-135 group Neisseria meningitidis (5 micrograms)
- Polysaccharide of the Y group Neisseria meningitidis (5 micrograms)
- Tetanus toxoid carrier protein (44 micrograms)
- Sucrose
- Trometamol
- Sodium chloride
- Water for injections
